Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

1. These authors contributed equally: Claus Garbe, Reinhard Dummer.

2. These authors jointly supervised this work: Christian Blank, Georgina V. Long.

Authors and Affiliations

1. Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

   Claus Garbe & Teresa Amaral

2. Department of Dermatology, University Hospital Zürich (USZ), Zürich, Switzerland

   Reinhard Dummer

3. Faculty of Medicine, University of Zürich (UZH), Zürich, Switzerland

   Reinhard Dummer

4. Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

   Rodabe N. Amaria, Elizabeth M. Burton, Sapna P. Patel & Hussein A. Tawbi

5. Department of Skin Cancer, Cancer Immunotherapy and Development Therapeutics, Instituto Nazionale Tumouri IRCCS Fondazione G. Pascale, Napoli, Italy

   Paolo A. Ascierto

6. Nantes University, Nantes, France

   Brigitte Dreno

7. Faculty of Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

   Alexander M. M. Eggermont

8. Comprehensive Cancer Centre Munich of the Technical University Munich and the Ludwig Maximilians University, Munich, Germany

   Alexander M. M. Eggermont

9. Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Kiel, Germany

   Axel Hauschild

10. Department of Dermatology, Medical University of Vienna, Vienna, Austria

    Christoph Hoeller

11. Department of Dermatology, Venerology and Allergology, Frankfurt University Hospital, Frankfurt, Germany

    Roland Kaufmann

12. Université Paris Cite, AP-HP Department of Dermatology, Hôpital Saint-Louis Paris, Paris, France

    Celeste Lebbe

13. Department of Surgery and Medicine, Unit of Medical Oncology, University of Perugia, Perugia, Italy

    Mario Mandala

14. Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia

    Alexander M. Menzies, Richard A. Scolyer & Georgina V. Long

15. Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia

    Alexander M. Menzies, Richard A. Scolyer & Georgina V. Long

16. Faculty of Medicine & Health, The University of Sydney, Sydney, NSW, Australia

    Alexander M. Menzies, Richard A. Scolyer & Georgina V. Long

17. Medical & Surgical Dermatology Service, Hospital Universitario Virgen Macarena, Sevilla, Spain

    David Moreno

18. Department of Medical Oncology, Lausanne University Hospital, Lausanne, Switzerland

    Olivier Michielin

19. Mount Vernon Cancer Centre, Northwood, UK

    Paul Nathan

20. Department of Medical Oncology, Gustave Roussy and Paris-Saclay University, Villejuif, France

    Caroline Robert

21. Department of Dermatology, University Hospital Essen, Essen, Germany

    Dirk Schadendorf

22. German Cancer Consortium, Heidelberg Partner Site Essen, Essen, Germany

    Dirk Schadendorf

23. University of Manchester, Manchester, UK

    Paul C. Lorigan

24. Department of Pathology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands

    Bart A. van de Wiel

25. Department of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands

    Christian Blank

26. Leiden University Medical Centre (LUMC), Leiden, The Netherlands

    Christian Blank

Corresponding authors

Correspondence to Claus Garbe or Reinhard Dummer.

Competing interests

C.G. declares funding from and has an advisory role at Merck Sharp & Dhome (MSD), Novartis, NeraCare, Bristol-Meyers Squibb (BMS) and Philogen. R.D. has an advisory role at Novartis, MSD, BMS, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer and touchIME. T.A. has an advisory role at CeCaVa, Novartis, NeraCare, BMS, Pierre Fabre, Sanofi, SkylineDx and iFIT. R.A. declares funding from Novartis. P.A. has an advisory role at BMS, Roche-Genentech, MSD, Novartis, Merck Serono, Pierre Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Nektar, Italfarmaco, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTx, Replimmune and Bayer. B.D. declares funding from BMS, Fabre Oncology, Novartis, Almirall and Sun Pharma. A.E. declares funding from Agenus, BioInvent, BioNTech, Brenus, CatalYm, Ellipses, Epics, Galecto, GenOway, IO Biotech, IQVIA, Merck & Co./MSD, Pfizer, Sairopa, Sellas, SkylineDX, TigaTX and Trained Immunity TX. A.H. has an advisory role at Amgen, BMS, MerckPfizer, MSD/Merck, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme, Novartis Pharma, Eisai, Immunocore, Replimune, Seagen, IO Biotech, Dermagnostix, Incyte, NeraCare, Highlight Therapeutics, Huya Biosciences and Kyowa Kirin. C.H. declares funding from BMS, Novartis, Amgen, Almirall, Pierre Fabre and Sanofi. R.K. has an advisory role at Abbvie, Amgen, BMS, Celgene, Galderma, Jannsen, MSD, Novartis, Roche and UCB. C.L. declares funding from BMS, Roche, MSD, Novartis, Amgen, Merck Serono, Sanofi, Pierre Fabre, Pfizer, Incyte, Avantis, InflaRx and Jazz Pharmaceuticals. M.M. has an advisory role at Novartis, BMS, Sanofi, Pierre Fabre and MSD. A.M. has an advisory role at BMS, MSD, Novartis, Roche, Pierre-Fabre and QBiotics. O.M. has an advisory role at BMS, Roche-Genentech, MSD, Novartis, Merck Serono, Pierre Fabre, AstraZeneca and Immunocore. P.N. has an advisory role at MSD, Novartis, Merck, BMS, Pfizer, Immunocore and Ipsen. S.P. declares funding from BMS, Foghorn Therapeutics, Ideaya, InxMed, Lyvgen Biopharma, Novartis, Provectus Biopharmaceuticals, Seagen, Syntrix Bio, TriSalus Life Sciences, Advance Knowledge in Healthcare, Cardinal Health, Castle Biosciences, Delcath, Immatics, Immunocore and Replimune. C.R. has an advisory role at BMS, Roche, Pierre Fabre, Novartis, Sanofi, Pfizer, MSD and AstraZeneca. D.S. has an advisory role at Merck Serono, Amgen, Immunocore, 4SC, Pierre Fabre, Pfizer, Philogen, Regeneron, Nektar, Novartis, Sanofi, Ultimovacs, Haystack, Astra Zeneca, Daiichi Sankyo, Agenus, InFlarX, Agenus, Replimune, Erasca, SunPharma, Immatics, Neracare, Seagen and Bioalta. P.L. has an advisory role at BMS, Merck, Novartis, GlaxoSmithKline (GSK), Amgen, Chugai, PierreFabre, NeraCare, Roche and OncologyEducationCanada. R.S. has an advisory role at MetaOptima Technology, F. Hoffmann-La Roche, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, MSD, NeraCare, Amgen, BMS, Myriad Genetics and GSK. H.T. has an advisory role at BMS, Novartis, Merck, Genentech, GSK, EMD Serono, Eisai, Dragonfly Therapeutics, RAPT Therapeutics, Boxer Capital, Karyopharm, Lovance, Jazz Pharmaceuticals and Medicenna. C.B. has an advisory role at MSD, Novartis, BMS, Roche, GSK, AstraZeneca, Pfizer, Lilly, GenMAB, Pierre Fabre, Third Rock ventures, NanoString and 4SC. G.L. has an advisory role at Agenus, Amgen, Array Biopharma, Boehringer Ingelheim International, BMS, Evaxion, Hexal AG, Highlight Therapeutics, Innovent Biologics, MSD, Novartis, OncoSec, PHMR, Pierre Fabre, Provectus, Qbiotics and Regeneron. All other authors declare no competing interests.

Reprints and permissions